Business

In 2021, even the most vulnerable economies will have access to vaccines: the WHO

COVAX increased its vaccination program agreements for the most vulnerable people worldwide, reaching 2 billion doses.

3 min read


  • That news came after COVAX’s initiative to bring vaccines to “developing countries” was deemed tightly funded and contractual.
In 2021, even the most vulnerable economies will have access to vaccines: the WHO
In 2021, even the most vulnerable economies will have access to vaccines: the WHO

The World Health Organization (WHO)announced that its global vaccine delivery mechanism, COVAX, “now has agreements on access to nearly 2 billion doses of various promising vaccine candidates,” significantly increasing its offering.

In addition, it is estimated that at least 1.3 billion doses “will be given to the 92 low- and middle-income economies eligible for COVAX AMC (Advance Market Commitment)”.

It’s worth noting that this news came after the COVAX initiative to bring vaccines to “developing countries” was deemed tightly funded and contractual. Some experts even pointed out that the likelihood of an even distribution of COVID-19 vaccines is rapidly decreasing.

The new agreements, however, represent good news as a statement said “first deliveries are expected to begin in the first quarter of 2021, depending on regulatory approvals and countries preparing for delivery,” which will ensure protection, “for those on most vulnerable populations around the world “.

The Latin American nations that receive donations through COVAX include Bolivia, El Salvador, Haiti, Nicaragua, Honduras, St. Lucia, and St. Vincent and the Grenadines. However, it is expected that all Latin American and Caribbean countries will receive vaccines at the same time (regardless of whether they pay for them or not).

Likewise, the new commitments announced include the anticipated purchase of 170 million doses of the vaccine developed by AstraZeneca and 500 million doses of the pharmaceutical company Janssen from Johnson Johnson, which recently and successfully completed the vaccine study in Colombia.

Similar Posts